The seventh batch of nationally organized drug centralized procurement will produce the proposed winning results in Nanjing, Jiangsu Province on July 12. The official winning results will be released after the public announcement. 60 kinds of drugs were successfully purchased in this centralized purchase. The average price of the selected drugs was reduced by 48%. Calculated based on the agreed purchase volume, it is expected to save 18.5 billion yuan per year.
Involves high blood pressure , lung cancer and other medications
The public benefits widely
This centralized procurement of drugs involves 31 treatment categories, including hypertension, diabetes , anti-infection, digestive tract diseases and other common diseases, chronic disease medications, and lung cancer , liver cancer , kidney cancer , intestinal cancer and other major diseases, the people have benefited widely and have a strong sense of gain.
Taking lenvatinib capsules, a first-line targeted drug for liver cancer, as an example, each capsule has dropped from an average of 108 yuan to an average of 18 yuan, which can save 8,100 yuan in one treatment cycle. has included sustained-controlled release dosage forms for the first time in the field of blood pressure lowering. has reduced the price of nifedipine controlled-release tablets by 58% and metoprolol sustained-release tablets by 53%, significantly reducing the medication burden on patients with hypertension. The antiviral drug and oseltamivir dropped from an average of 4.5 yuan to 1 yuan per tablet.
In addition, there are 4 original research companies including tigecycline from Pfizer of the United States, micafungin from Japan's Astellas, ebastine from Spain's Emero, and diaprol from Italy's Bracco Xinyi. The drug was selected and the price was reduced by an average of 67%.
The reserve supply mechanism was introduced for the first time
to ensure stable clinical use
In terms of procurement rules, this centralized procurement adheres to the basic principle of "linking volume and price, integrating recruitment and procurement" and the working mechanism of "national organization, alliance procurement, and platform operation". And make further adjustments and optimizations to strengthen supply security.
introduces a backup supply mechanism for the first time. Each province will have a main supplier and a backup supplier at the same time to ensure stable clinical use.
Patients across the country will use the selected products after the price reduction of this centralized purchase in November this year.
Since the establishment of the National Medical Insurance Administration in 2018, it has carried out 7 batches of nationally organized centralized procurement of drugs, covering a total of 294 kinds of drugs. According to the pre-collective price, It is estimated that the amount involved accounts for about 35% of the annual procurement of chemical drugs and biological drugs by public medical institutions. Centralized and volume-based procurement has become an important mode of drug procurement in public hospitals.
In the next step, the National Medical Insurance Administration will work with relevant departments to guide various localities and selected companies to implement the winning results, to ensure that patients across the country can use the selected products after price reductions in this centralized purchase in November 2022.
Source Hanzhong Daily
